129 related articles for article (PubMed ID: 15670295)
1. Efficient screening for ovarian cancers using a combination of tumor markers CA602 and CA546.
Saito M; Aoki D; Susumu N; Suzuki A; Suzuki N; Udagawa Y; Nozawa S
Int J Gynecol Cancer; 2005; 15(1):37-44. PubMed ID: 15670295
[TBL] [Abstract][Full Text] [Related]
2. [Preclinical and clinical studies on a tumor marker, galactosyltransferase associated with tumor (GAT), in ovarian cancer (second report)--clinical significance of GAT and comparison with other tumor markers].
Nozawa S; Udagawa Y; Ito K; Susumu N; Sasaki H; Aoki D
Gan To Kagaku Ryoho; 1993 Feb; 20(2):279-85. PubMed ID: 8434967
[TBL] [Abstract][Full Text] [Related]
3. [Studies on clinical usefulness of new tumor markers of ovarian cancer, CA54/61 and CA602--III. Measurement of serum samples from patients with various benign or malignant diseases].
Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hashimoto M
Gan To Kagaku Ryoho; 1994 May; 21(6):823-32. PubMed ID: 8185340
[TBL] [Abstract][Full Text] [Related]
4. [CA546, CA602].
Yamashita H; Kataoka F; Aoki DA
Nihon Rinsho; 2010 Jul; 68 Suppl 7():688-90. PubMed ID: 20960852
[No Abstract] [Full Text] [Related]
5. [CA546, CA602].
Nozawa S; Fukuchi T
Nihon Rinsho; 1999 Dec; 57 Suppl():470-3. PubMed ID: 10778167
[No Abstract] [Full Text] [Related]
6. Clinical characteristics of a newly developed ovarian tumour marker, galactosyltransferase associated with tumour (GAT).
Udagawa Y; Aoki D; Ito K; Uejima T; Uemura M; Nozawa S
Eur J Cancer; 1998 Mar; 34(4):489-95. PubMed ID: 9713298
[TBL] [Abstract][Full Text] [Related]
7. [CA546, CA602].
Fukuchi T; Nozawa S
Nihon Rinsho; 2005 Aug; 63 Suppl 8():647-50. PubMed ID: 16149602
[No Abstract] [Full Text] [Related]
8. [Clinical value of a new serum tumor marker CA602 in ovarian cancers].
Suzuki M; Sekiguchi I; Ohwada M; Aida I; Tamada T
Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1454-60. PubMed ID: 2170549
[TBL] [Abstract][Full Text] [Related]
9. [Clinical usefulness of the combination assay of CA 125, SLX, and CA 72-4 in patients with ovarian cancer].
Kobayashi H; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Nov; 41(11):1731-5. PubMed ID: 2574209
[TBL] [Abstract][Full Text] [Related]
10. Differential diagnosis of ovarian cancer, benign ovarian tumor and endometriosis by a combination assay of serum sialyl SSEA-1 antigen and CA125 levels.
Iwanari O; Miyako J; Date Y; Nakayama S; Kijima S; Moriyama M; Takahashi K; Yoshino N; Karino K; Endoh J
Gynecol Obstet Invest; 1990; 29(1):71-4. PubMed ID: 1972127
[TBL] [Abstract][Full Text] [Related]
11. Changes in CA602 and CA546 concentrations in patients during in-vitro fertilization and embryo transfer, and ovarian hyperstimulation syndrome.
Takamatsu K; Kasuga M; Nakano M; Udagawa Y; Yoshimura Y; Nozawa S
Hum Reprod; 1997 Mar; 12(3):441-5. PubMed ID: 9130736
[TBL] [Abstract][Full Text] [Related]
12. [Applications of tumor markers to the screening of endometrial and ovarian cancers].
Nozawa S; Takamatsu K; Tsukazaki K; Udagawa Y
Nihon Rinsho; 1996 Jun; 54(6):1665-73. PubMed ID: 8691627
[TBL] [Abstract][Full Text] [Related]
13. An immunoenzymometric assay for a CA125-like antigen, CA602.
Mochizuki H; Sato I; Nagoya K; Furusako S; Yamauchi T; Masuko H; Sato H; Morishita H; Yajima M; Sasaki H
J Clin Lab Anal; 1992; 6(2):84-90. PubMed ID: 1383480
[TBL] [Abstract][Full Text] [Related]
14. Elevation of multiple serum markers in patients with stage I ovarian cancer.
Woolas RP; Xu FJ; Jacobs IJ; Yu YH; Daly L; Berchuck A; Soper JT; Clarke-Pearson DL; Oram DH; Bast RC
J Natl Cancer Inst; 1993 Nov; 85(21):1748-51. PubMed ID: 8411259
[TBL] [Abstract][Full Text] [Related]
15. A new CA125-like antigen (CA602) recognized by two monoclonal antibodies against a newly established ovarian clear cell carcinoma cell line (RMG-II).
Nozawa S; Yajima M; Sasaki H; Tsukazaki K; Aoki D; Sakayori M; Udagawa Y; Kobayashi T; Sato I; Furusako S
Jpn J Cancer Res; 1991 Jul; 82(7):854-61. PubMed ID: 1715339
[TBL] [Abstract][Full Text] [Related]
16. [Tumor markers of ovarian cancer].
Nozawa S
Rinsho Byori; 1992 Apr; 40(4):349-53. PubMed ID: 1593759
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive acidic protein and CA 125 levels in patients with ovarian cancer.
Castelli M; Battaglia F; Scambia G; Panici PB; Ferrandina G; Mileo AM; Mancuso S; Ferrini U
Oncology; 1991; 48(1):13-7. PubMed ID: 1987493
[TBL] [Abstract][Full Text] [Related]
18. [Mass-screening for ovarian cancer by transvaginal ultrasonography--study on tumor markers at the second screening].
Sato S; Sugo T; Maruyama H; Saito Y; Hasuo Y
Nihon Sanka Fujinka Gakkai Zasshi; 1994 Nov; 46(11):1247-53. PubMed ID: 7844443
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous measurement of CA 125, CA 19-9, tissue polypeptide antigen, and immunosuppressive acidic protein to predict recurrence of ovarian cancer.
Kamiya N; Mizuno K; Kawai M; Kano T; Furuhashi Y; Tomoda Y
Obstet Gynecol; 1990 Sep; 76(3 Pt 1):417-21. PubMed ID: 2381619
[TBL] [Abstract][Full Text] [Related]
20. [Diagnosis and follow-up of ovarian cancer by a combination assay of serum sialyl SSEA-1 antigen and CA125 levels].
Iwanari O; Miyako J; Date Y; Moriyama M; Yoshino N; Kijima S; Nakayama S; Ryuhkoh K; Moriyama M; Hata T
Nihon Gan Chiryo Gakkai Shi; 1989 Jun; 24(6):1256-60. PubMed ID: 2571650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
